Endo invests in early-stage companies innovating chronic disease care, with a focus on diabetes.
Location
Los Angeles, CA, US
Founded
2013
Endo Investors focuses on early-stage companies improving outcomes for large patient populations affected by chronic diseases, with a particular emphasis on diabetes and other major global health issues. The firm targets game-changing ventures in the life sciences sector, typically investing in seed and Series B rounds.
Endo's portfolio includes Cecelia Health, which has raised $13 million to date. Founded by Eric Edidin, the firm was created in response to a perceived deficit of early-stage capital for companies addressing diabetes and other chronic conditions. Endo is backed by mission-oriented investors and aims to support innovative solutions that can significantly impact patient care and outcomes in the chronic disease space.
Endo Investors - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies4
Current Portfolio Count3
Total Portfolio Exits1
Top Investment Stages
Seed3 (75.0%)
Series B1 (25.0%)
Stage Mix
Seed 75%Series B 25%
Concentration shown as share of disclosed investments by stage.
